HeartSciences Statistics
Total Valuation
HeartSciences has a market cap or net worth of $9.12 million. The enterprise value is $8.54 million.
Important Dates
The next estimated earnings date is Monday, December 15, 2025, after market close.
| Earnings Date | Dec 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HeartSciences has 3.07 million shares outstanding. The number of shares has increased by 105.27% in one year.
| Current Share Class | 3.07M |
| Shares Outstanding | 3.07M |
| Shares Change (YoY) | +105.27% |
| Shares Change (QoQ) | +21.72% |
| Owned by Insiders (%) | 2.79% |
| Owned by Institutions (%) | 4.15% |
| Float | 2.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,500.93 |
| Forward PS | n/a |
| PB Ratio | 2.30 |
| P/TBV Ratio | 6.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,365.67 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.47, with a Debt / Equity ratio of 0.62.
| Current Ratio | 1.47 |
| Quick Ratio | 0.93 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.32 |
Financial Efficiency
Return on equity (ROE) is -193.24% and return on invested capital (ROIC) is -84.67%.
| Return on Equity (ROE) | -193.24% |
| Return on Assets (ROA) | -69.65% |
| Return on Invested Capital (ROIC) | -84.67% |
| Return on Capital Employed (ROCE) | -238.15% |
| Revenue Per Employee | $417 |
| Profits Per Employee | -$584,569 |
| Employee Count | 15 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.00 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.94% in the last 52 weeks. The beta is 2.59, so HeartSciences's price volatility has been higher than the market average.
| Beta (5Y) | 2.59 |
| 52-Week Price Change | -2.94% |
| 50-Day Moving Average | 3.47 |
| 200-Day Moving Average | 3.49 |
| Relative Strength Index (RSI) | 30.07 |
| Average Volume (20 Days) | 27,955 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HeartSciences had revenue of $6,250 and -$8.77 million in losses. Loss per share was -$8.20.
| Revenue | 6,250 |
| Gross Profit | 3,610 |
| Operating Income | -8.15M |
| Pretax Income | -8.77M |
| Net Income | -8.77M |
| EBITDA | -8.12M |
| EBIT | -8.15M |
| Loss Per Share | -$8.20 |
Full Income StatementBalance Sheet
The company has $2.79 million in cash and $1.95 million in debt, giving a net cash position of $845,368 or $0.28 per share.
| Cash & Cash Equivalents | 2.79M |
| Total Debt | 1.95M |
| Net Cash | 845,368 |
| Net Cash Per Share | $0.28 |
| Equity (Book Value) | 3.14M |
| Book Value Per Share | 1.38 |
| Working Capital | 1.40M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.35 million and capital expenditures -$3,157, giving a free cash flow of -$7.35 million.
| Operating Cash Flow | -7.35M |
| Capital Expenditures | -3,157 |
| Free Cash Flow | -7.35M |
| FCF Per Share | -$2.39 |
Full Cash Flow StatementMargins
| Gross Margin | 57.76% |
| Operating Margin | -130,416.37% |
| Pretax Margin | -140,296.54% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HeartSciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -105.27% |
| Shareholder Yield | -105.27% |
| Earnings Yield | -93.47% |
| FCF Yield | -78.36% |
Analyst Forecast
The average price target for HeartSciences is $10.50, which is 253.54% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.50 |
| Price Target Difference | 253.54% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 17, 2024. It was a reverse split with a ratio of 1:100.
| Last Split Date | May 17, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
HeartSciences has an Altman Z-Score of -20.27 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -20.27 |
| Piotroski F-Score | 1 |
